Albrecht Stenzinger, M.D.


Jonathan Nowak, M.D.,Ph.D.

This product includes the webinar and SAM credit

Description: Approaches to calculating, reporting, and interpreting Tumor Mutational Burden (TMB) testing will be discussed in this second of two updates on the broader use of TMB as a potentially prognostic and predictive tool in clinical care. Dr. Stenzinger will provide an overview of how large-scale efforts to harmonize TMB measurement may bolster the potential clinical utility of TMB reporting.

Duration: 1 hr

Level of Instruction: Basic

Last day to purchase course and claim credit: December 31, 2021

Maximum SAM credit available: 1.0

This webinar is part 2 of a two-part series exploring the role of TMB testing in relationship to other tumor biomarkers as well as the standardization of TMB testing.

This program has been supported through an educational grant from Bristol-Myers Squibb.

AMP is pleased to collaborate in the Immunotherapy Collaborative of Oncology Networked Communities, IC-ONC.  IC-ONC is a global information network in which multidisciplinary healthcare providers, responsible for treating patients with cancer, are connected via education.  

Please be sure to visit www.ic-onc.org to learn more about the collaborative and all it has to offer.

How to claim credit: To earn SAM credit, all learners must watch the webinar, achieve a minimum score of 80% on the online quiz, and complete an online survey. To access the quiz, click "Submit credit" on the course homepage or click on "My Credit" on the menu to the left and then "submit credit" for the appropriate course.

This course is approved by the American Board of Pathology for 1.0 SAM credits.Physicians should only claim credit commensurate with the extent of their participation in the activity. Participants must successfully complete the online modular exams (answering at least 80% of the questions in a topic module correctly).

* You may not submit SAMs and CME/CMLE credit for the same content.

You may also be interested in:

Note: Members of AMP can access many of the webinars at no cost or a deep discount. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

Course Information
Course Date:
August 15, 2019
Course Objectives
  • Discuss the current state of TMB calculation and reporting as well as efforts to standardize this process across laboratories.
  • Understand the potential clinical utility of TMB and how it should be interpreted, especially in the context of other immunotherapy biomarkers.
  • Harness available information to improve implementation of molecularly targeted cancer diagnostics and therapies in the clinical setting.
Pre-Test for Making TMB Relevant in the Clinic: Best Practices for TMB Calculation, Reporting, and Interpretation (+SAM)
Making TMB Relevant in the Clinic: Best Practices for TMB Calculation, Reporting, and Interpretation (+SAM)
Post-Test for Making TMB Relevant in the Clinic: Best Practices for TMB Calculation, Reporting, and Interpretation (+SAM)
How to Claim SAM Credit
Individual topic purchase: Selected
American Board of Pathology
Self-Assessment Module: 1.00
Stenzinger Presentation +SAM
AMP Regular Member: $0.00
AMP Technologist Member: $0.00
AMP Associate Member: $0.00
Non-member Price: $0.00